Generated by AI
Compugen Ltd. is a clinical-stage therapeutic discovery and development company focused on cancer immunotherapy and autoimmune diseases. Compugen Ltd. uses its AI- and machine learning-powered Unigen platform to identify novel drug targets, validate biological pathways, and advance therapeutic and diagnostic biomarker candidates. Its current work centers on developing antibodies and other biologic product candidates for oncology and immune-related conditions, with programs designed to address unmet needs in solid tumors and inflammatory diseases. The company operates across Israel, the United States, and Europe, supporting research, development, and commercial collaboration activities. Headquartered in Holon, Israel, Compugen Ltd. plays a role in the biotechnology market as a platform-driven company that combines computational discovery with experimental development to build differentiated drug candidates.
WebsiteAzrieli Center
Holon, 5885849
Israel
The latest articles about CGEN.
Compugen Ltd (CGEN) posted $3.8 million in Q3 2026 revenue, completed MAIA-ovarian enrollment with data due by Q1 2027, and holds $117.5 million in cash to fund operations into 2029.
Summary of May 18's posts. Generated by AI.
Summary of Mar 2's posts. Generated by AI.
Summary of Dec 17's posts. Generated by AI.
Investors talking about CGEN also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.